Are­na's lead drug miss­es on PhII in AD, thwack­ing stock, but com­pa­ny sol­diers on in­to Phase III

Amit Mun­shi’s tenure at Are­na Phar­ma­ceu­ti­cals has al­most ex­clu­sive­ly been one of suc­cess: Tak­ing the reins of a com­pa­ny in the Nas­daq gut­ter, he’s steered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER